Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of three bifidobacteria to prevention or treatment of acute pancreatitis

A technology for acute pancreatitis and bifidobacteria, which is applied in the direction of application, medical preparations containing active ingredients, anti-inflammatory agents, etc., and can solve the problems of no bifidobacteria and less understanding of the role of bifidobacteria

Pending Publication Date: 2022-07-15
THE AFFILIATED SIR RUN RUN SHAW HOSPITAL OF SCHOOL OF MEDICINE ZHEJIANG UNIV
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In the treatment of acute pancreatitis, the bifidobacterium used is Bifidobacterium longum, and the bifidobacterium preparation used for patients is a multi-bacteria combination preparation, including Bifidobacterium longum, Lactobacillus acidophilus and Enterococcus faecalis, There are currently no regimens using bifidobacterium monobacteria, and the role of other bifidobacteria is poorly understood

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of three bifidobacteria to prevention or treatment of acute pancreatitis
  • Application of three bifidobacteria to prevention or treatment of acute pancreatitis
  • Application of three bifidobacteria to prevention or treatment of acute pancreatitis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1 Preparation of B.animalis ATCC25527, B.pseudocatenulatum ATCC27919 and B.adolescentis ATCC15703

[0040] To prepare active bacterial agent:

[0041] Bifidobacterium animalis and Bifidobacterium adolescentis were cultured strictly anaerobic in BBL medium. The bacterial liquid in the logarithmic growth phase was centrifuged at 8000g for 10 min at 4°C, the supernatant was removed, the bacterial slurry was washed twice with sterile saline, and the bacterial slurry was resuspended in 30% (v / v) glycerol. Store in -80°C refrigerator.

[0042] Bifidobacterium pseudocatenulatum was cultured strictly anaerobic in MRS medium. The bacterial liquid in the logarithmic growth phase was centrifuged at 8000g for 10 min at 4°C, the supernatant was removed, the bacterial slurry was washed twice with sterile saline, and the bacterial slurry was resuspended in 30% (v / v) glycerol. Store in -80°C refrigerator.

[0043] Before use, dilute the active bacterial agent to 1×10 with s...

Embodiment 2

[0044]Example 2 Bifidobacterium animalis, B. pseudocatenulatum and B. adolescentis for the prevention of mild acute pancreatitis (MAP):

[0045] 2.1 Establish the MAP model of acute pancreatitis:

[0046] The acute pancreatitis model was induced by intraperitoneal injection of cerulein. The cerulein was dissolved in physiological saline, and one injection of cerulein (25 μg / kg body weight) was injected every hour, and 7 injections were continuously injected.

[0047] 2.2 Prevention of mild acute pancreatitis (MAP):

[0048] PBS group (representing that the flora was not cleared): PBS was continuously supplemented.

[0049] Abx gavage group (all representative bacteria were cleared): mice were gavaged with ampicillin (33.2mg), neomycin (33.2mg), metronidazole (33.2mg) and vancomycin (16.7mg) every day Composition of antibiotic mixture for 5 days. After the fifth day of gavage, antibiotics (1 g / L for ampicillin, neomycin, and metronidazole, and 0.5 g / L for vancomycin) were a...

Embodiment 3

[0057] Example 3 Bifidobacterium animalis for the prevention of severe acute pancreatitis (SAP)

[0058] 3.1 Establish SAP model of acute pancreatitis:

[0059] The acute pancreatitis model was induced by intraperitoneal injection of cerulein. The cerulein was dissolved in the normal saline, and an injection of cerulein (25 μg / kg body weight) was injected every hour for 10 consecutive injections, and one injection of LPS (7.5 mg / Kg) was intraperitoneally injected.

[0060] 3.2 Normal mice supplement Bifidobacterium animalis to prevent severe acute pancreatitis:

[0061] 20-23g male C57BL / 6J mice at about 7 weeks of age were randomly divided into control group (PBS) and Bifidobacterium animalis treatment group (PBS+B. animalis), 5 mice in each group, provided with controllable feeding conditions.

[0062] Modeling of cerulein 48 hours after single bacterial colonization. The result is as Figure 5-6 shown, Figure 5 Serum amylase concentrations in SAP mice 12 hours after m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of Bifidobacteria pseudococcus tenophorae, Bifidobacteria or Bifidobacteria animations in the aspect of preventing or treating acute pancreatitis, and particularly discloses application of Bifidobacteria pseudococcus tenophorae, Bifidobacteria animations or Bifidobacteria animations in the aspect of preventing or treating acute pancreatitis. The invention provides an application of Bifidobacterium pseudocausate, Bifidobacterium adolescence or Bifidobacterium aniis in a product for preventing or treating acute pancreatitis, and the application of the Bifidobacterium pseudocausate, the Bifidobacterium adolescence or the Bifidobacterium aniis in a product for preventing or treating acute pancreatitis. The invention further provides a preparation method of the Bifidobacterium pseudocausate, the Bifidobacterium adolescence and the Bifidobacterium aniis. The strain can relieve alveolar cell injury and inflammation infiltration, reduce the concentration of amylase in serum and reduce the death rate of acute pancreatitis, is used for preparing probiotic medicines, pharmaceutical compositions, health-care foods, functional foods and feeds for treating acute pancreatitis, and has a wide application prospect.

Description

technical field [0001] The invention relates to the technical field of acute pancreatitis, in particular to the application of bifidobacteria in preventing or treating acute pancreatitis. Background technique [0002] Acute pancreatitis is an inflammatory reaction caused by various etiologies that cause pancreatic enzymes to be activated in the pancreas, causing autodigestion, edema, hemorrhage and even necrosis of pancreatic tissue. Clinically, it is characterized by acute epigastric pain, nausea, vomiting, fever and increased blood pancreatic enzymes. The severity of the lesions varies, and the mild cases are mainly pancreatic edema, which is more common in clinical practice. The disease is often self-limiting and the prognosis is good. It is also called mild acute pancreatitis. A small number of severe cases of pancreatic hemorrhage and necrosis, often secondary to infection, peritonitis and shock, have a high fatality rate, which is called severe acute pancreatitis. Ac...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K35/745A61P1/18A61P29/00A23L33/135A23K10/18
CPCA61K35/745A61P1/18A61P29/00A23L33/135A23K10/18A23V2002/00A23V2400/513A23V2400/515A23V2400/535A61K2300/00A23V2200/32
Inventor 郭丰朱书李涵郭秀镠谢金炎
Owner THE AFFILIATED SIR RUN RUN SHAW HOSPITAL OF SCHOOL OF MEDICINE ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com